Theralase Technologies Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Roger J. Dumoulin-White
- Full Time Employees
- 16
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 41 Hollinger Road Toronto ON Canada M4B 3G4
- IPO Date
- Nov 2, 2004
- Website
- theralase.com
- Similar Companies
- Business
- Theralase Technologies Inc. operates as a clinical-stage pharmaceutical firm, dedicated to the investigation and advancement of sophisticated Photo Dynamic Compounds (PDCs) and their specialized drug formulations across Canada, the United States, and international markets. This innovative approach targets the elimination of various cancers, bacteria, and viruses. Concurrently, the company designs, develops, manufactures, and distributes its patented super-pulsed laser technology, specifically cleared for treating chronic knee discomfort and utilized off-label for ameliorating a spectrum of nerve, muscle, and joint conditions. A primary focus for Theralase is TLD-1433, known as Ruvidar™, which is currently undergoing a pivotal Phase II clinical study for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ. Enrollment for this study is nearing completion, with the company aiming for New Drug Application submissions to Health Canada and the FDA by the fourth quarter of 2026, potentially leading to regulatory approval in early 2027. Recent preclinical findings have also demonstrated the efficacy of Ruvidar® against Herpes Simplex Virus Type 1 and the potential for an X-ray activated version, Rutherrin®, in various cancer models. Beyond its drug development, Theralase markets its Cool Laser Therapy (CLT) systems, which include devices like the TLC-2000, to healthcare professionals. These systems utilize dual-wavelength, super-pulsed laser technology to penetrate tissue deeply, facilitating pain relief, reducing inflammation, and accelerating cellular healing. Founded in 1994, Theralase Technologies Inc. is headquartered in Toronto, Canada, and continues its mission of "Destroying Cancer at the Speed of Light®" and "Healing Pain at the Speed of Light®."
Company News
Theralase(R) to Present at ThinkEquity Conference
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Closes C$3.6 Million Brokered Financing
Theralase(R) Announces $5 Million Brokered LIFE Offering
Theralase(R) Grants Stock Options
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Theralase(R) Lists Warrants on the TSXV
Theralase(R) Releases Q1 2026 Financial Statements
Theralase(R) Closes C$4.8 Million Offering
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
Theralase(R) Announces $4 Million Brokered LIFE Offering
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Theralase(R) Closes $CAN 2.66 Million Financing
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress